WESTPORT, CT (Reuters Health) – In a 1-year study, children receiving fluticasone for asthma grew significantly more rapidly than children receiving beclomethasone, researchers report in the Archives of Pediatric and Adolescent Medicine for November.
Dr. Fernando M. de Benedictis from the University of Perugia, Italy, and colleagues randomly assigned 343 asthmatic children, 4 to 11 years of age, to beclomethasone or fluticasone 200 µg administered twice daily via a dry powder inhaler.
During the trial children receiving fluticasone had a significantly greater growth velocity compared with those receiving beclomethasone (5.04 versus 4.05 cm/year, respectively, p < 0.001), the researchers found.
Although both medications improved lung function, there were significant differences in favor of fluticasone in terms of peak expiratory flow (p < 0.001), forced expiratory volume in 1 second (p < 0.001), forced vital capacity (p = 0.008) and forced expiratory flow from 25% to 75% of forced vital capacity (p = 0.02), Dr. de Benedictis's group reports.
Adverse events were similar in both groups and there were no significant difference in serum or urinary cortisol levels.
"On the grounds of this study, fluticasone should be chosen in preference to beclomethasone for children with asthma, especially if moderate doses are required," the investigators advise.
Arch Pediatr Adolesc Med 2001;155:1248-1254.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!